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Abstract
Integration of human immunodeficiency virus type 1 (HIV-1) into the host genome is catalyzed by
the viral integrase (IN) and preferentially occurs within transcriptionally active genes. During the
early phase of HIV-1 infection, the incoming viral preintegration complex (PIC) recruits the
integrase interactor 1 (INI1)/hSNF5, a chromatin remodeling factor which directly binds to HIV-1
IN. The impact of this event on viral replication is so far unknown, although it has been
hypothesized that it could tether the preintegration complex to transcriptionally active genes, thus
contributing to the bias of HIV integration for these regions of the genome. Here, we demonstrate
that while INI1 is dispensable for HIV-1 transduction, it can facilitate HIV-1 transcription by
enhancing Tat function. INI1 bound to Tat and both the repeat (Rpt) 1 and Rpt 2 domains of INI1
were required for efficient activation of Tat-mediated transcription. These results suggest that the
incoming PICs might recruit INI1 to facilitate proviral transcription.
Finding
Integrase (IN) catalyses the integration of viral DNA into
the host genome, which is an essential step of human
immunodeficiency virus type 1 (HIV-1) replication [1].
Integrase interactor 1 (INI1), also known as hSNF5, a core
component of ATP-dependent chromatin remodeling
SWI/SNF complex [2], directly interacts with HIV-1 IN
and stimulates its activity in vitro [3]. INI1 contains three
conserved regions including two direct imperfect repeats,
repeat Rpt 1 and Rpt2, and a carboxyl (C)-terminal coiled-
coil domain [4]. INI1 also acts as a tumor suppressor, as
mutations in the ini1 gene leads to aggressive pediatric
atypical teratoid and malignant rhabdoid tumors (AT/
MRTs) [5], suggesting a role for the SWI/SNF complex in
control of the cell cycle. In fact, INI1 induces cell cycle
arrest at G1 through repression of cyclin D1 transcription
[6,7].
INI1 has been reported to interact with other viral pro-
teins, including the Epstein-Barr virus nuclear antigen 2
(EBNA2) [8-10], human papillomavirus E1 [11], and her-
pesvirus K8 [12] as well as cellular factors c-MYC [13],
ALL1 (MLL) [14], GADD34 [15], and p53 [16]. During
the early phase of the HIV-1 life cycle, the incoming HIV-
1 preintegration complex (PIC) triggers the exportin-
mediated cytoplasmic export of and associates with INI1
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nuclear domain 10 (ND10)/PML oncogenic domain
(POD) is a target of DNA viruses such as herpes simplex
virus-1 (HSV-1), human cytomegalovirus (CMV), adeno-
virus, papillomavirus, and Epstein-Barr virus (EBV) [19].
The recruitment of PML to HIV-1 PICs could promote its
association with PML-interacting proteins such as the his-
tone acetyltransferase (HAT) CBP/p300, or with other
transcription factors. Similarly, the binding of INI1 to the
HIV-1 PICs may trigger the recruitment of the SWI/SNF
complex to the PIC, possibly targeting HIV integration to
actively transcribed regions of the genome or facilitating
subsequent expression of the provirus. To probe these
issues, we investigated the potential roles of INI1 and PML
in HIV-1 integration and transcription.
To analyze the effect of INI1 on HIV-1 transduction effi-
ciency, we first used lentiviral vector-mediated RNA inter-
ference to stably knockdown INI1 protein in CD4+ LTR-β-
Gal HeLa-derived P4.2 cells [20]. Oligonucleotides with
the following sense and antisense sequences were used for
the cloning of small hairpin RNA (shRNA)-encoding
sequences in lentiviral vector: INI1, 5'-
GATCCCCAGGCAACAGGTCATGTTCATTCAAGAGAT-
GAACATGACCTGTTGCCTTTTTTGGAAA-3' (sense), 5'-
AGCTTTTCCAAAAAAGGCAACAGGTCATGTTCATCTCTT
GAATGAACATGACCTGTTGCCTGGG-3' (antisense). The
oligonucleotides above were annealed and subcloned
into the BglII-HindIII site of pSUPER [21]. To construct
pLVshRNA against INI1 (pLV281), the BamHI-SalI frag-
ment of pSUPER-INI1i (pSP281) plasmid was subcloned
into the BamHI-SalI site of pRDI292 [22], downstream
from an RNA polymerase III promoter within the context
of an HIV-1-derived self-inactivating lentiviral vector con-
taining a puromycin marker allowing for the selection of
the transduced cells. We used the vesicular stomatitis virus
(VSV)-G pseudotyped HIV1 based vector system as previ-
ously described [23,24]. RT-PCR measurements demon-
strated a very effective downregulation of ini1 mRNA in
cells transduced with the lentiviral vector expressing the
INI1 shRNA (Fig. 1a). These and control P4.2 cells were
then exposed to a VSV-G-pseudotyped, HIV-1-derived len-
tiviral vector expressing GFP under the control of the E1Fα
promoter. FACS analyses performed forty-eight hours
later revealed that the INI1 knockdown (INI1i) and con-
trol P4.2 cells (C) were equally susceptible to lentiviral
vector-mediated transduction (Fig. 1b). As well, an HIV
vector could effectively transduce INI1-deficient MON
cells derived from a malignant rhabdoid tumor (data not
shown), suggesting that INI1 is not essential for HIV-1
integration. We then measured rates of HIV-1 replication
in the INI1 knockdown P4.2 cells. After infection with an
HIV-1 X4 strain, p24 viral capsid levels were significantly
reduced in the supernatant of INI1 knockdown cells com-
pared with control P4.2 cells (Fig. 1c). In view of the nor-
mal transduction susceptibility of these cells, this results
suggested a role for INI1 in later step of replication.
INI1 is dispensable for HIV-1 transductionFigure 1
INI1 is dispensable for HIV-1 transduction. a. Inhibition 
of ini1 expression by shRNA-producing lentiviral vector. 
Ethidium bromide-stained agarose gel analysis of RT-PCR 
amplification products of cytoplasmic RNA from INI1 knock-
down P4.2 cells (INI1i) as well as in P4.2 cells transduced 
with a control (C) lentiviral vector. Cytoplasmic RNA was 
obtained using RNeasy kit (Qiagen) and RT-PCR was per-
formed using SuperScript one-step RT-PCR with Platinum 
Taq kit (Invitrogen) with following primers: ini1, 5'-TCT-
GGAGGCGACTAGCCACTGTG-3' (forward primer) and 
5'-GATCACAGCTGGGTCATGGTCATC-3' (reverse 
primer); beta-actin, 5'-TGACGGGGTCACCCACACTGT-
GCCCATCTA-3' (forward primer) and 5'-CTAGAAG-
CATTTGCGGTGGACGATGGAGGC-3' (reverse primer). 
b. Transduction efficiency in the same cells was determined 
by GFP fluorescence-activated cell sorter (FACS) analysis 
with a FACStrak apparatus (Becton Dickinson) 2 days after 
exposure to VSV-G-pseudotyped GFP-expressing HIV-1-
derived lentiviral vector at the indicated MOI. Experiments 
were done in duplicate and columns represent the mean per-
centage of transduced cells, with mean fluorescence intensity 
(MFI) indicated below. c. Reduced HIV-1 replication in INI1 
knockdown cells. INI1 knockdown P4.2 cells were infected 
with HIV-1 at a MOI of 0.5. HIV-1 replication was assayed by 
p24 ELISA in the culture supernatant 6 days later.
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Retrovirology 2006, 3:47 http://www.retrovirology.com/content/3/1/47To test the possibility that INI1 might modulate HIV-1
transcription, CD4+ HeLa P4.2 cells were cotransfected
with plasmids expressing Tat and/or INI1, together with a
Tat-responsive HIV-1-LTR-driven luciferase reporter plas-
mid [25]. INI1 significantly increased Tat-mediated trans-
activation of the HIV-1 LTR (about 4 fold), while it had a
negligible effect in the absence of transactivator (Fig. 2a).
As well, INI1 could coactivate the Tat-mediated transcrip-
tion of a stably integrated HIV1-LTR-β-gal construct, as
assessed by measuring LacZ activity in the transfected P4.2
cells (Fig. 2b). To identify the domain of Tat essential for
response to INI1, we used the C-terminal deletion
mutants of Tat, Tat72 and Tat86 [26]. INI1 could fully
coactivate their transcriptional activities (Fig. 2c), indicat-
ing that the C-terminal domain of Tat (amino acids 73–
101) is dispensable for transcriptional activation by INI1.
Next, we found that Tat-mediated transcription was signif-
icantly inhibited in INI1 knockdown P4.2 cells compared
to control, INI1-expressing P4.2 cells (Fig. 2d). Recipro-
cally, Tat activity was markedly increased in INI1 deficient
MON cells when INI1 was reintroduced by transfection
(Fig. 2e). Taken together, these data demonstrate that
INI1 synergizes with Tat to activate HIV-1 transcription.
To probe the mechanism of this phenomenon, we per-
formed co-immunoprecipitation analyses on extracts of
293T cells expressing FLAG-tagged Tat- and HA-tagged
INI1 (Fig. 3). Both proteins could be immunoprecipitated
with either anti-Flag or anti-HA antibody, indicating that
they formed a complex, whether directly or indirectly.
To identify the domain of INI1 important for boosting Tat
function, we co-expressed Tat and various INI1 deletion
mutants [7] in 293T cells transfected with the HIV-1-LTR-
luciferase plasmid (Fig. 4a). The full-length protein (INI1)
and the two deletion mutants (20.2 and 1.2) still contain-
ing repeat Rpt 1 and Rpt2 domains increased Tat-medi-
ated HIV-1 transcription by a factor ten (Fig. 4b). In
contrast, mutants 3B and 27B, which lack the Rpt2
domain, could still bind Tat (Fig. 4c), but enhanced tran-
scription by only 2-fold. These results suggest that both
Rpt1 and Rpt2 domains of INI1 participate in allowing for
full coactivation of Tat-mediated HIV-1 transcription.
Interestingly, both Rpt1 and Rpt2 domain are required for
the formation of a functional SWI/SNF complex.
Tat-mediated transactivation is essential for HIV-1 replica-
tion. Tat exerts its transcriptional effect by binding of P-
TEFb, a transcription elongation factor composed of cyc-
lin T1 and CDK9, and the interaction of Tat with P-TEFb
and TAR leads to hyperphosphorylation of the C-terminal
domain (CTD) of RNA polymerase II (Pol II) thus increas-
ing the processivity of RNA Pol II [27]. In addition, it has
been suggested that Tat plays a critical role in the assembly
of the transcription complex (TC) during preinitiation
INI1 coactivates Tat-mediated HIV-1 transcriptionFigure 2
INI1 coactivates Tat-mediated HIV-1 transcription. 
a. P4.2 cells (2 × 104 cells per well) were cotransfected with 
100 ng of pHIV-1-LTR-Luc [25], 100 ng of pcDNA3-Tat101-
FLAG [41], and/or 200 ng of pCGN-INI1 [7]. Luciferase assay 
was performed 24 h later. All transfections utilized equal 
total amounts of plasmid DNA owing to the addition of 
empty vector into the transfection mixture. Results were 
obtained through three independent transfections. Relative 
stimulation of luciferase activity (fold) is shown. b. 100 ng of 
pcDNA3-Tat101-FLAG, and/or 200 ng of pCGN-INI1 were 
cotransfected into P4.2 cells in triplicate. Beta-galactosidase 
activity was measured 24 h later. c. P4.2 cells were cotrans-
fected with 100 ng of pHIV-1-LTR-Luc, 50 ng of pH2F Tat 
(Tat86) or pH2Tat (Tat72) [26], and/or 200 ng of pCGN-
INI1 and performed luciferase assays 24 h later. d. 100 ng of 
pHIV-1-LTR-Luc, and/or 100 ng of pcDNA3-Tat101-FLAG 
were cotransfected into INI1 knockdown P4.2 cells (INI1i) 
or P4.2 cells transduced with a control (C) lentiviral vector 
and luciferase assays were performed 24 h later. e. INI1 defi-
cient MON cells (2 × 104 cells per well) were cotransfected 
with 100 ng of pHIV-1-LTR-Luc, 50 ng of pcDNA3-Tat101-
FLAG, and/or 200 ng of pCGN-INI1 and luciferase assays 
performed 24 h later.
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SNF chromatin remodeling complex promotes this step
rather than the elongation of viral transcripts. Corre-
spondingly, our data are consistent with recent reports
indicating that SWI/SNF is recruited onto the HIV-1-LTR
promoter in Tat-dependent manner [28-30]. These other
studies further revealed that, in addition to INI1, Tat also
recruits Brm or the closely related Brg-1, the ATPase subu-
nit of the SWI/SNF complex. INI1 and Brg-1 then appear
to synergize with the p300 histone acetyltransferase to
activate the HIV-1 promoter. Both the binding of Tat to
Brm and the synergistic activation of the HIV LTR by Tat
and the SWI/SNF complex were found to require Tat
acetylation on lysine 50 [28-30].
During the early phase of the HIV-1 life cycle, not only
INI1 but also PML is exported to the cytoplasm where it
can be found in association with the incoming preintegra-
tion complex [17,18]. The recruitment of PML to PICs
could subsequently promote the association of PML-inter-
acting proteins such as histone acetyltransferase (HAT)
CBP/p300 or other transcription regulators to the HIV
promoter. P300 was shown to bind to HIV1 IN and
enhances the catalytic activity of this recombinase by
acetylation [31]. Interestingly, Marcello et al. found that
cyclin T1, the cellular cofactor of Tat responsible for phos-
phorylating the C-terminus of Pol II polymerase, hence of
augmenting the processivity of HIV1 transcription, is
recruited to PML nuclear bodies through a direct interac-
tion with the PML protein [32]. Therefore, PML might reg-
ulate Tat-mediated transcription through its association
with cyclin T1. However, we failed to observe significant
effects of PML on Tat-mediated transcription as well as
HIV-1 transduction efficiency in HeLa P4.2 cells in which
levels of PML were decreased by at least 90% by RNA
interference (data not shown). A possible influence of
PML on HIV replication thus remains to be demonstrated,
perhaps using other cellular systems and more effective
knockdowns of this gene.
Retroviral integration favors active genes, MLV concentrat-
ing in and around promoters while HIV tends to land in
the transcribed region of genes [33-35]. The determinant
of such selectivity is unknown. High mobility group pro-
tein A1 (HMG-A1), barrier-to-autointegration factor
(BAF) and Ku have been suggested to influence this step,
as these proteins are found in both HIV-1 and MLV PICs
[1]. Another candidate is lens epithelium-derived growth
factor (LEDGF)/p75, which was identified as an IN-inter-
acting protein [36] that can enhance HIV-1 IN strand
transfer activity in vitro [36] and influence the intracellular
trafficking of HIV-1 but not MLV IN [37]. Accordingly, it
was recently demonstrated that LEDGF can affect HIV1
integration site selection in human cells [38]. Whether
INI1, which binds to HIV-1 IN but not to MLV IN [39],
also participates in this process remains to be established.
While this protein is dispensable for HIV-1 transduction
per se (Fig. 1 and reference [18]), Maroun et al. recently
reported that INI1 interferes with early steps of HIV-1
infection [40]. Moreover, we did not ask whether integra-
tion site selection was modified in INI1 knockdown cells.
While further studies are required to clarify the roles of
factors that associate with the retroviral preintegration
complex, the present work suggests that some of them
may exert their effect after the provirus is established.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
YA carried out luciferase assay, immunoprecipitation, and
was involved in drafting the manuscript. FS and PT carried
out luciferase assays, western blotting, and PML knock-
down study. AT participated in the construction of lentivi-
INI1 binds to TatFigure 3
INI1 binds to Tat. 293T cells were cotransfected with 5 µg 
of pcDNA3-Tat101-FLAG [41] and/or 5 µg of pCGN-HA-
INI1 [7]. Cells were lysed in buffer containing 50 mM Tris-
HCl (pH 8.0), 150 mM NaCl, 4 mM EDTA, 0.1% NP-40, 10 
mM NaF, 0.1 mM Na3VO4, 1 mM DTT and 1 mM PMSF. 
Lysates were pre-cleared with 30 µl of protein-G-sepharose 
(Amersham Biosciences). Pre-cleared supernatants were 
incubated with either 2 µg of anti-HA antibody (HA 11, 
Babco) or anti-FLAG antibody (M2, Sigma) at 4°C for 1 h. 
Following absorption of the precipitates on 30 µl of protein-
G-sepharose resin for 1 h, the resin was washed four times 
with 700 µl lysis buffer. Bound proteins were eluted by boil-
ing the resin for 5 min in 1× Laemmli sample buffer. The pro-
teins were then subjected to SDS-PAGE, followed by 
immunoblotting analysis using either anti-HA or anti-FLAG 
antibodies.
Tat
INI1
HA
FLAG
IP: HA FLAG HAFLAG HAFLAG
IgL
IgH
WB:
Tf: HA-INI1
 Tat- 
FLAG
HA-INI1 
    + 
 Tat- 
FLAG
1 2 3 4 5 6Page 4 of 6
(page number not for citation purposes)
Retrovirology 2006, 3:47 http://www.retrovirology.com/content/3/1/47ral vector expressing INI1 shRNA. DT participated in the
design of the study and in drafting the manuscript.
Acknowledgements
We thank Bastien Mangeat, Sandrine Vianin, and Elisabeth Buhlmann for 
discussion and help with the experiments, and Monsef Benkirane, Masakazu 
Hatanaka, Hiroyuki Sakai, Yoshihiro Kitamura, Richard Iggo, and Ganjam V. 
Kalpana for the gift of reagents. This work was supported by the Swiss 
National Science Foundation, the Ministry of Education, Culture, Sports, 
Science and Technology (MEXT) Grant-in-Aid for Young Scientists (B) 
(18790326), and the Naito Foundation.
References
1. Turlure F, Devroe E, Silver PA, Engelman A: Human cell proteins
and human immunodeficiency virus DNA integration.  Front
Biosci 2004, 9:3187-3208.
2. Wang W, Côté J, Xue Y, Zhou S, Khavari PA, Biggar SR, Muchardt C,
Kalpana GV, Goff SP, Yaniv M, Workman JL, Crabtree GR: Purifica-
tion and biochemical heterogeneity of the mammalian SWI-
SNF complex.  EMBO J 1996, 15:5370-5382.
3. Kalpana GV, Marmon S, Wang W, Crabtree GR, Goff SP: Binding
and stimulation of HIV-1 integrase by a human homolog of
yeast transcription factor SNF5.  Science 1994, 266:2002-2006.
4. Morozov A, Yung E, Kalpana GV: Structure-function analysis of
integrase interactor 1/hSNF5L1 reveals differential proper-
ties of two repeat motifs present in the highly conserved
region.  Proc Natl Acad Sci USA 1998, 95:1120-1125.
5. Versteege I, Sévenet N, Lange J, Rousseau-Merck M-F, Ambros P,
Handgretinger R, Aurias A, Delattre O: Truncating mutations of
hSNF5/INI1 in aggressive paediatric cancer.  Nature 1998,
394:203-206.
6. Ae K, Kobayashi N, Sakuma R, Ogata T, Kuroda H, Kawaguchi N, Shi-
nomiya K, Kitamura Y: Chromatin remodeling factor encoded
by ini1 induces G1 arrest and apoptosis in ini1-deficient cells.
Oncogene 2002, 21:3112-120.
7. Zhang Z-K, Davies KP, Allen J, Zhu L, Pestell RG, Zagzag D, Kalpana
GV: Cell cycle arrest and repression of cyclin D transcription
by INI1/hSNF5.  Mol Cell Biol 2002, 22:5975-5988.
8. Kwiatkowski B, Chen SYJ, Schubach WH: CKII site in Epstein-
Barr virus nuclear protein 2 controls binding to hSNF5/Ini1
and is important for growth transformation.  J Virol 2004,
78:6067-6072.
9. Wu DY, Kalpana GV, Goff SP, Schubach WH: Epstein-Barr virus
nuclear protein 2 (EBNA2) binds to a component of the
human SNF-SWI complex, hSNF5/Ini1.  J Virol 1996,
70:6020-6028.
10. Wu DY, Krumm A, Schubach WH: Promoter-specific targeting
of human SWI-SNF complex by Epstein-Barr virus nuclear
protein 2.  J Virol 2000, 74:8893-8903.
11. Lee D, Sohn H, Kalpana GV, Choe J: Interaction of E1 and hSNF5
proteins stimulates replication of human papillomavirus
DNA.  Nature 1999, 399:487-491.
12. Hwang S, Lee D, Gwack Y, Min H, Choe J: Kaposi's sarcoma-asso-
ciated herpesvirus K8 protein interacts with hSNF5.  J Gen
Virol 2003, 84:665-676.
13. Cheng SW, Davies KP, Yung E, Beltran RJ, Yu J, Kalpana GV: c-MYC
interacts with INI1/hSNF5 and requires the SWI/SNF com-
plex for transactivation function.  Nat Genet 1999, 22:102-105.
14. Rosenblatt-Rosen O, Rozovskaia T, Burakov D, Sedkov Y, Tillib S,
Blechman J, Nakamura T, Croce CM, Mazo A, Canaani E: The C-ter-
minal SET domains of ALL-1 and TRITHORAX interact with
the INI1 and SNR1 proteins, components of the SWI/SNF
complex.  Proc Natl Acad Sci USA 1998, 95:4152-4157.
15. Adler HT, Chinery R, Wu DY, Kussick SJ, Payne JM, Fornace AJ Jr,
Tkachuk DC: Leukemic HRX fusion proteins inhibit GADD34-
induced apoptosis and associate with the GADD34 and
hSNF5/INI1 proteins.  Mol Cell Biol 1999, 19:7050-7060.
16. Lee D, Kim JW, Seo T, Hwang SG, Choi E-J, Choe J: SWI/SNF com-
plex interacts tumor suppressor p53 and is necessary for the
activation of p53-mediated transcription.  J Biol Chem 2002,
277:22330-22337.
17. Turelli P, Doucas V, Craig E, Mangeat B, Klages N, Evans R, Kalpana
G, Trono D: Cytoplasmic recruitment of INI1 and PML on
Both Rpt1 and Rpt2 domains of INI1 are required for the efficient activation of Tat-mediated HIV-1 transcriptionFigure 4
Both Rpt1 and Rpt2 domains of INI1 are required for 
the efficient activation of Tat-mediated HIV-1 tran-
scription. a. Schematic representation of HA-tagged full-
length INI1 and its mutants. b. 293T cells (2 × 104 cells per 
well) were cotransfected with 100 ng of pHIV-1-LTR-Luc 
[25], 50 ng of pcDNA3-Tat101-FLAG [41], and/or 200 ng of 
pCGN-INI1 or its mutant (20.2, 1.2, 3B, 27B) [7] in triplicate 
and luciferase assays were performed 24 h later. c. 293T cells 
were cotransfected with 5 µg of pcDNA3-Tat101-FLAG and/
or 5 µg of pCGN-HA-INI1 or its mutant (20.2, 3B, 27B) and 
IP-western blotting was performed in the similar way as 
shown in Fig. 3. Asterisk denotes HA-INI1 or its mutant.
HA
HA
1
1
294
245
3B
27B
HA
HA
1 385
141
Rpt1 Rpt2
INI1
20.2
HA
181
1.2
385
385
0
200
400
600
800
1000
1200
R
e
la
ti
v
e
 l
u
c
if
e
ra
s
e 
a
c
ti
v
it
y
 (
fo
ld
) HIV-1-LTR-Luc
Tat:
INI1:
- + + + + + +
-- INI1 1.2 20.2 3B 27B
a.
b.
FLAG- 
Ta t10 1
HA-INI1 αHA
αFLAG
IP: FLAGHA FLAGHA FLAG
IgL
Ig H
WB:
Tf:
HA-INI1 
     + 
FLAG- 
 Tat101
1 2 3 4 5 6 7 8
FLAGHA HA
   20.2 
     + 
FLAG- 
 Tat101
    3B  
     + 
FLAG- 
 Tat101
   27B 
     + 
FLAG- 
 Tat101




c .Page 5 of 6
(page number not for citation purposes)
Retrovirology 2006, 3:47 http://www.retrovirology.com/content/3/1/47Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
incoming HIV preintegration complexes: interference with
early steps of viral replication.  Mol Cell 2001, 7:1245-1254.
18. Boese A, Sommer P, Gaussin A, Reimann A, Nehrbass U: Ini1/
hSNF5 is dispensable for retrovirus-induced cytoplasmic
accumulation of PML and does not interfer with integration.
FEBS Lett 2004, 578:291-296.
19. Maul GG: Nuclear domain 10, the site of DNA virus transcrip-
tion and replication.  BioEssays 1998, 20:660-667.
20. Charneau P, Mirambeau G, Roux P, Paulous S, Buc H, Clavel F: HIV1
reverse transcription. A termination step at the center of
the genome.  J Mol Biol 1994, 241:651-662.
21. Brummelkamp TR, Bernard R, Agami R: A system for stable
expression of short interfering RNAs in mammalian cells.
Science 2002, 296:550-553.
22. Bridge AJ, Pebernard S, Ducraux A, Nicoulaz A-L, Iggo R: Induction
of an interferon response by RNAi vectors in mammalian
cells.  Nat Genet 2003, 34:263-264.
23. Naldini L, Blömer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM,
Trono D: In vivo gene delivery and stable transduction of non-
dividing cells by a lentiviral vector.  Science 1996, 272:263-267.
24. Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D: Multiply atten-
uated lentiviral vector achieves efficient gene delivery in
vivo.  Nat Biotechnol 1997, 15:871-875.
25. Ariumi Y, Kaida A, Hatanaka M, Shimotohno K: Functional cross-
talk of HIV1 Tat with p53 through its C-terminal domain.
Biochem Biophys Res Commun 2001, 287:556-561.
26. Endo S, Kubota S, Siomi H, Adachi A, Oroszlan S, Maki M, Hatanaka
M: A region of basic amino-acid cluster in HIV-1 Tat protein
is essential for trans-acting activity and nucleolar localiza-
tion.  Virus Genes 1989, 3:99-110.
27. Brady J, Kashanchi F: Tat gets the "green" light on transcription
initiation.  Retrovirology 2005, 2:69.
28. Mahmoudi T, Parra M, Vries RGJ, Kauder SE, Verrijzer CP, Ott M,
Verdin E: The SWI/SNF chromatin-remodeling complex is a
cofactor for Tat transactivation of the HIV promoter.  J Biol
Chem 2006, 281:19960-19968.
29. Tréand C, du Chéné I, Brés V, Kiernan R, Benarous R, Benkirane M,
Emiliani S: Requirement for SWI/SNF chromatin-remodeling
complex in Tat-mediated activation of the HIV-1 promoter.
EMBO J 2006, 25:1690-1699.
30. Agbottah E, Deng L, Dannenberg LO, Pumfery A, Kashanchi F: Effect
of SWI/SNF chromatin remodeling complex on HIV-1 Tat
activated transcription.  Retrovirology 2006, 3:48.
31. Cereseto A, Manganaro L, Gutierrez MI, Terreni M, Fittipaldi A, Lusic
M, Marcello A, Giacca M: Acetylation of HIV-1 integrase by
p300 regulates viral integration.  EMBO J 2005, 24:3070-3081.
32. Marcello A, Ferrari A, Pellegrini V, Pegoraro G, Lusic M, Beltram F,
Giacca M: Recruitment of human cyclin T1 to nuclear bodies
through direct interaction with the PML protein.  EMBO J
2003, 22:2156-2166.
33. Trono D: Picking the right spot.  Science 2003, 300:1670-1671.
34. Schröder ARW, Shinn P, Chen H, Berry C, Ecker JR, Bushman F:
HIV-1 integration in the human genome favors active genes
and local hotspots.  Cell 2002, 110:521-529.
35. Wu X, Li Y, Crise B, Burgess SM: Transcription start regions in
the human genome are favored targets for MLV integration.
Science 2003, 300:1749-1751.
36. Cherepanov P, Maertens G, Proost P, Devreese B, Van Beeumen J,
Engelborghs Y, De Clercq E, Debyser Z: HIV-1 integrase forms
stable tetramers and associates with LEDGF/p75 protein in
human cells.  J Biol Chem 2003, 278:372-381.
37. Llano M, Vanegas M, Fregoso O, Saenz D, Chung S, Peretz M, Poe-
schla EM: LEDGF/p75 determines cellular trafficking of
diverse lentiviral but not murine oncoretroviral integrase
proteins and is a component of functional lentiviral preinte-
gration complexes.  J Virol 2004, 78:9524-9537.
38. Ciuffi A, Llano M, Poeschla E, Hoffmann C, Leipzig J, Shinn P, Ecker JR,
Bushman F: A role for LEDGF/p75 in targeting HIV DNA inte-
gration.  Nat Med 2005, 11:1287-1289.
39. Yung E, Sorin M, Wang E-J, Perumal S, Ott D, Kalpana GV: Specifi-
city of interaction of INI1/hSNF5 with retroviral integrases
and its functional significance.  J Virol 2004, 78:2222-2231.
40. Maroun M, Delelis O, Coadou G, Bader T, Ségéral E, Mbemba G, Petit
C, Sonigo P, Rain J-C, Mouscadet J-F, Benarous R, Emiliani S: Inhibi-
tion of early steps of HIV-1 replication by SNF5/Ini1.  J Biol
Chem 2006, 281:22736-43.
41. Brés V, Kiernan RE, Linares LK, Chable-Bessia C, Plechakova O, Tre-
and C, Emiliani S, Peloponese JM, Jeang KT, Coux O, Scheffner M,
Benkirane M: A non-proteolytic role for ubiquitin in Tat-medi-
ated transactivation of the HIV1 promoter.  Nat Cell Biol 2003,
5:754-761.Page 6 of 6
(page number not for citation purposes)
